Michael Makris Shares French Regulatory Update: Marstacimab (Hympavzi) Not Recommended for Severe Haemophilia A or B
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, UK. Editor-in-Chief of Research and Practice in Thrombosis and Haemostasis, shared a post on Linkedin:
“Interesting development from France. The French authorities assessed marstacimab (Hympavzi) and concluded that it has no place in the therapeutic strategy for severe haemophilia A or B without inhibitors.
They questioned the robustness of the comparative assessment against other approved therapies and pointed to uncertainties in terms of safety.
The document is in French but Google translate does a pretty good job if you do not speak French. I attach the Google translate version of the conclusion. ”
Check out here for more.
Find more posts on Hemostasis Today.
-
Mar 7, 2026, 16:05Iyas Daghlas: DOACs Use, Genetic Reduction of Coagulation Factors and Risk of Cerebral Venous Thrombosis
-
Mar 7, 2026, 15:58Aurelio Maggio: The Mission and The Projects We Are Advancing for Rare Hematologic Diseases
-
Mar 7, 2026, 15:52Faizan Khan: The Importance of Cancer Site in Bleeding Risk Stratification for Cancer-Associated VTE
-
Mar 7, 2026, 15:50Heghine Khachatryan: How DOACs Can Cause False-Positive FVIII Inhibitor Results
-
Mar 7, 2026, 15:43Gevorg Tamamyan Joins The London Global Cancer Week Steering Group
-
Mar 7, 2026, 15:36Kenneth Monaghan: Empowering Stroke Survivors’ Self-Efficacy Through Neuroplasticity and Daily Activity
-
Mar 7, 2026, 15:31Tagreed Alkaltham: Practical Strategies for Navigating Blood Shortage Periods
-
Mar 7, 2026, 15:28Philip Wells Honored with the 2026 ISTH Esteemed Career Award
-
Mar 7, 2026, 15:27Gashaw Arega: A Challenging Case of Acute Immune Thrombocytopenia in an Adolescent